Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
Alpha Tau (Nasdaq: DRTS) announced on May 7, 2026 that the first patient in Italy was treated with Alpha DaRT for locally advanced pancreatic cancer at the University of Verona Pancreas Institute. The feasibility/safety protocol permits both EUS-guided and percutaneous delivery, expanding physician access and joining concurrent trials in France and the U.S.
The single-session, image-guided insertion targets patients who received prior chemotherapy or are unfit for systemic therapy; no efficacy or survival data were reported.
Alpha Tau (Nasdaq: DRTS) announced that top-line data from a clinical study of Alpha DaRT in combination with pembrolizumab for elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma will be presented as a podium paper at AHNS, July 21, 2026 in Boston.
The abstract reports complete top-line results from Hadassah Medical Center and highlights prior monotherapy safety data across the US, Europe, Israel, and Japan; no numeric efficacy or safety figures are included in this announcement.
Alpha Tau (Nasdaq: DRTS) reported pooled results from two first-in-human Alpha DaRT pancreatic cancer trials presented at DDW 2026. Across 19 evaluable patients the pooled analysis showed 100% local disease control (15 stable disease, 4 partial responses). Of 26 treated subjects, 8 device-associated adverse events occurred in 7 patients (27%), nearly all resolving within two weeks. The therapy was delivered via a streamlined outpatient EUS-guided procedure. Results were presented from Hadassah Medical Center and support advancement into the ongoing U.S. multicenter IMPACT trial.
Alpha Tau (Nasdaq: DRTS) announced that an abstract titled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer” was accepted to the 2026 ASCO Annual Meeting (May 29–June 2, 2026).
The pooled analysis combines safety and efficacy data from 58 patients across three prospective EUS-guided intratumoral Alpha DaRT studies at centers in Montreal and Jerusalem. The abstract will be published on the ASCO website on May 21, 2026 at 5:00 PM ET. Alpha Tau said this acceptance, alongside ASCO GI and DDW presentations, reflects growing scientific interest in its pancreatic program.
Alpha Tau (NASDAQ: DRTS) announced FDA approval of an IDE supplement to expand its U.S. IMPACT pancreatic cancer pilot trial. The supplement adds 10 patients receiving gemcitabine/nab-paclitaxel and increases total trial size from 30 to 40 patients. Recruitment completion shifts from Q2 to Q3 2026 to allow site approvals and added enrollment.
Alpha Tau (Nasdaq: DRTS) announced the first European treatment of a pancreatic cancer patient in the ACAPELLA multicenter trial on April 23, 2026. ACAPELLA tests Alpha DaRT® plus capecitabine for inoperable locally advanced pancreatic ductal adenocarcinoma after mFOLFIRINOX. The procedure occurred at CHU Grenoble Alpes under endoscopic ultrasound guidance. The trial includes an embedded immune biomarker program and runs alongside the U.S. IMPACT pancreatic trial.
Alpha Tau (Nasdaq: DRTS) announced acceptance of the first-ever oral presentation of Alpha DaRT pancreatic cancer clinical results at Digestive Disease Week (DDW) 2026.
The abstract, “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” will be presented May 2, 2026 at 10:30am Central by Dr. Harold Jacob, using combined data from two Hadassah Medical Center protocols. According to the company, these foundational studies informed the IMPACT pilot now enrolling in the U.S. and ongoing planning toward a future pivotal study.
Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET. The presentation is virtual and Mr. Levy is available for one‑on‑one investor meetings scheduled through Sidoti representatives.
Alpha Tau (NASDAQ: DRTS) reported full-year 2025 results and a corporate update highlighting regulatory, clinical and manufacturing progress. Key items: $76.9M cash, Japanese marketing approval for head and neck cancer, five parallel U.S. trial approvals, positive pancreatic data (ORR 22%/DCR 81%), and a commercial-scale New Hampshire license.
The company reported a $42.6M net loss for 2025 and outlined upcoming recruitment and safety readouts through 2026.
Alpha Tau Medical (Nasdaq: DRTS) received Shonin (MHLW) marketing approval in Japan for Alpha DaRT to treat unresectable locally advanced or locally recurrent head and neck cancer on Feb 24, 2026.
The approval is the platform's first regulatory clearance outside Israel and requires a post-market surveillance study enrolling 66 patients across five Japanese centers. The company plans discussions on reimbursement and further clinical evaluation with Japanese regulators and clinicians.